ARID2 and infection: Notably, treatment of A549 cells with siRNAs that target BRD9 or GLTSCR1, but not BRD7 or ARID2, led to a reproducible (although not statistically significant) reduction in the ability of IFN‐α2 to fully protect cells from infection with the IFN‐sensitive vesicular stomatitis virus (VSV) (Fig EV1C).